Transcriptional control of apolipoprotein A-I gene expression in diabetes

Area of Science:

• Cardiovascular Medicine
• Metabolic Disorders
• Molecular Biology

Background:

• Cardiovascular disease is the primary cause of death in diabetic patients.
• Low high-density lipoprotein (HDL) cholesterol levels are common in diabetes, increasing cardiovascular risk.
• HDL cholesterol's cardioprotective effects are linked to its main protein, apolipoprotein (apo) A-I.

Purpose of the Study:

• To review alterations in the transcriptional control of apo A-I in diabetes.
• To examine the impact of diabetes-related nutritional and hormonal changes on apo A-I expression.
• To identify mechanisms modulating apo A-I gene expression for therapeutic development.

Main Methods:

• Literature review focusing on transcriptional control of apo A-I.
• Analysis of studies on animal models and cell cultures of diabetes.
• Examination of the effects of hyperglycemia, hypoinsulinemia, ketoacidosis, and insulin resistance mediators on apo A-I promoter activity.

Main Results:

• Diabetes, particularly high glucose concentrations, reduces apo A-I expression in animal models and cell cultures.
• Nutritional and hormonal factors common in diabetes, including hyperglycemia and hypoinsulinemia, affect apo A-I promoter activity.
• Mediators of insulin resistance like fatty acids, cytokines, and prostanoids also influence apo A-I gene expression.

Conclusions:

• Understanding the mechanisms that regulate apo A-I gene expression in diabetes is crucial.
• Identifying these mechanisms can lead to the development of novel therapeutic agents.
• Therapeutic strategies aimed at increasing plasma apo A-I and HDL concentrations may mitigate cardiovascular risk in diabetes.